A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia.

A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia.

An open-label phase I/II study of single-agent obatoclax determined a maximum tolerated dose (MTD) and schedule, safety, and efficacy in older patients (≥ 70 yr) with untreated acute myeloid leukemia (AML).Phase I evaluated the safety of obatoclax infused for 3 hours on 3 consecutive days (3 h × 3 d...

Full description

Bibliographic Details
Main Authors: Aaron D Schimmer, Azra Raza, Thomas H Carter, David Claxton, Harry Erba, Daniel J DeAngelo, Martin S Tallman, Carolyn Goard, Gautam Borthakur
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4186779?pdf=render

Internet

http://europepmc.org/articles/PMC4186779?pdf=render

Similar Items